ClinicalTrials.gg
RecruitingNCT06650488Clopido-SNAP 2Updated Nov 20, 2026

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

A Phase 4 interventional study of Clopidogrel and Aspirin in Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia and Staphylococcus Aureus Bloodstream Infection, sponsored by Todd C. Lee MD MPH FIDSA. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Todd C. Lee MD MPH FIDSA · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Nov 12, 2026Start date movedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention.

Unlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it.

This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119).

If positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.

02

Conditions studied

  • Staphylococcus Aureus Endocarditis
  • Staphylococcus Aureus Septicemia
  • Staphylococcus Aureus Bloodstream Infection

Keywords

  • S. aureus bactremia
  • S. aureus bloodstream infection
  • S. aureus endocarditis
  • aspirin
  • clopidogrel
03

In context

Endocarditis

173 studies on the registry are indexed under Endocarditis; 56 are open to participants now.

This study's planned enrollment of 300 is above the median of 92 across 86 interventional studies indexed under Endocarditis.

Browse Endocarditis studies →

Lead sponsor

Todd C. Lee MD MPH FIDSA is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The participant must meet all inclusion and exclusion criteria for the SNAP

Platform (NCT05137119) and also the following inclusion and exclusion criteria:

Inclusion criteria

Inclusion Criteria:

  • Patient is taking (or will imminently start) aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease)

Exclusion criteria

Exclusion Criteria:

  • Active bleeding (allowing up to 120 hours from platform entry to randomize in the event anti-thrombotic therapy is resumed)
  • Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days
  • Pregnancy or lactation
  • Known receipt of clopidogrel, prasugrel, or ticagrelor within the last month
  • Allergy to clopidogrel
  • Concomitant receipt of an oral factor Xa inhibitor (apixaban, rivaroxaban, or edoxaban) or dabigatran
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Change to clopidogrel 75mg per day

    Patients will have their aspirin discontinued and start clopidogrel.

    Drug: Clopidogrel

  • Active comparator
    Continue aspirin

    Patients will continue their existing aspirin

    Drug: Aspirin

Interventions

  • Patients will change from aspirin to clopidogrel (without loading dose)

  • Patients will continue their existing aspirin.

06

What researchers measure

Primary outcomes

  1. Desirability of Outcome Ranking (DOOR)

    Desirability of Outcome Ranking (DOOR) - an ordinal outcome with 5 levels defined: Rank 1 - Alive without complication Rank 2 - Alive with 1 complication Rank 3 - Alive with 2 complications Rank 4 - Alive with 3 complications Rank 5 - Dead Complications include: 1. Clinical failure: Absence of resolution of clinical signs and symptoms of S. aureus bacteremia such that no additional antibiotic therapy is required or anticipated. 2. Infectious Complications: Including new endocarditis; new evidence of other deep metastatic foci (e.g., osteomyelitis or deep abscess); relapse of bacteremia after a patient has sterilized their initial blood cultures; readmission for subsequent care of S. aureus bacteremia; need for unplanned source control procedures 3. Serious adverse drug event (Common Terminology Criteria class 4) due to study drug OR adverse drug event (classes 1-3) leading to discontinuation of the study drug * Ties broken by length of stay for index hospitalization

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Secondary outcomes

  1. Clinical Failure

    Defined as the absence of resolution of clinical signs and symptoms of S. aureus bacteremia such that no additional antibiotic therapy is required or anticipated for its treatment.

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  2. Serious Adverse Event or Adverse Event Leading to Discontinuation

    Defined as a serious adverse drug event (Common Terminology Criteria for Adverse Events (CTCAE) class 4) presumed due to study drug OR adverse drug event (CTCAE classes 1-3) leading to discontinuation of the study drug

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  3. All cause mortality

    Death from any cause

    Time frame: At Days 14, 28, 42 and 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  4. Infectious Complications

    Defined as new endocarditis; new evidence of other deep metastatic foci (e.g., osteomyelitis or deep abscess); relapse of bacteremia after a patient has sterilized their initial blood cultures; readmission for subsequent care of S. aureus bacteremia; need for unplanned source control procedures. New implies that the complication was not suspected at enrollment and is not a function of delay to diagnostic testing.

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  5. Clinically relevant major bleeding

    This will be defined according to the criteria of the International Society on Thrombosis and Haemostasis as one or more of the following: fatal bleeding; symptomatic bleeding in a critical area or organ (including hemorrhagic stroke); bleeding that causes a fall in hemoglobin level of ≥20 g/L; or bleeding that requires a transfusion of 2 or more units of whole blood or red cells. For bleeds into non-critical areas, we will also record the site of bleeding.

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  6. Clinically relevant venous thromboembolic events

    This will be defined as an acute objectively confirmed deep vein thrombosis (upper extremity, lower extremity, other such as portal vein, cerebral vein, splanchnic vein) and/or segment or proximal pulmonary embolism, which is symptomatic and/or necessitates specific treatment. Below knee DVT and superficial thrombophlebitis are not included. Pulmonary embolism needs to be, segmental or proximal. Subsegmental pulmonary embolisms are not included as they have poor interrater reliability and may represent artefact in up to 50% of cases.

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  7. Clinically relevant stroke

    Stroke is defined as the acute onset of focal neurological dysfunction caused by brain, spinal cord, or retinal vascular injury because of infarction (ischemia). Ideally, at least one of the following should be present to confirm the diagnosis of stroke: confirmation by neurology, stroke specialist, or neurosurgical specialist, brain imaging (e.g., CT scan, MRI scan, or cerebral vessel angiography compatible with acute ischemia). If the acute focal signs represent a worsening of a previous deficit, these signs must persist for more than 24 hours and be accompanied by an appropriate new MRI or CT scan finding. In the absence of neuroimaging, a staff neurologist consult which makes the diagnosis of stroke will be considered.

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  8. Clinically relevant acute myocardial infarction

    Patients with S. aureus bacteremia often have substantial physiological stresses which can be associated with rises in cardiac troponin (demand ischemia). For the purposes of this outcome, acute myocardial infarction is captured as a type 1 myocardial infarction: detection of rise and/or fall of cardiac biomarkers with at least one value above the 99th percentile of the upper reference limit together with evidence of myocardial ischemia. For the purposes of this pragmatic trial, such a myocardial infarction will be inferred from the opinions of the staff cardiologist, intensivist, or general internal medicine specialist. The peak troponin value will be recorded, and a redacted copy of the relevant consultant's note and ECGs will be uploaded for audit.

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  9. Clinically relevant arterial thromboembolic event

    Clinical history compatible with sudden worsening of end organ or limb perfusion and confirmation by imaging (e.g., CT angiography, arterial doppler) or need for urgent surgery or thrombolysis.

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  10. Length of stay

    Amongst survivors, the length of inpatient stay for the index hospitalization.

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

07

Study locations

3 of 3 sites recruiting
  • NL and Labrador Health Services- Health Sciences Centre
    St. John's, Newfoundland and Labrador NL A1B 3V6, Canada
    Recruiting
  • NL and Labrador Health Services- St. Clare's Mercy Hospital
    St. John's, Newfoundland and Labrador NL A1C 5B8, Canada
    Recruiting
  • McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
    Montreal, Quebec H4A3S1, Canada
    Recruiting
    • Fatima Amari · Contactfatima.amari@rimuhc.ca · 514-934-1934
    • Todd C Lee, MD MPH FIDSA · Principal investigator
    • Emily G McDonald, MD MSc · Principal investigator
    • Matthew P. Cheng, MD SM · Sub investigator
    • Patrick Lawler, MD MPH · Sub investigator
    • Alexander Lawandi, MD MSc · Sub investigator
08

References and documents

Publications

  • Gentry CA, Williams RJ 2nd, Whitman CM, Thind SK, Kliewer BS. Staphylococcus aureus bacteraemia treatment outcomes in patients receiving ticagrelor vs a propensity-matched cohort receiving clopidogrel. Int J Antimicrob Agents. 2023 Apr;61(4):106743. doi: 10.1016/j.ijantimicag.2023.106743. Epub 2023 Feb 2. PubMed 36736927 ↗
  • Tong SYC, Mora J, Bowen AC, Cheng MP, Daneman N, Goodman AL, Heriot GS, Lee TC, Lewis RJ, Lye DC, Mahar RK, Marsh J, McGlothlin A, McQuilten Z, Morpeth SC, Paterson DL, Price DJ, Roberts JA, Robinson JO, van Hal SJ, Walls G, Webb SA, Whiteway L, Yahav D, Davis JS; Staphylococcus aureus Network Adaptive Platform (SNAP) Study Group. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. Clin Infect Dis. 2022 Nov 30;75(11):2027-2034. doi: 10.1093/cid/ciac476. PubMed 35717634 ↗
  • Caffrey AR, Appaneal HJ, LaPlante KL, Lopes VV, Ulloa ER, Nizet V, Sakoulas G. Impact of Clopidogrel on Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: a National Retrospective Cohort Study. Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0211721. doi: 10.1128/aac.02117-21. Epub 2022 Apr 13. PubMed 35416712 ↗

Individual participant data

Plan to share: Yes — All IPD that underlie results in the primary publication.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Beginning 1 year after publication with no end date

Access criteria: Post publication access to the trial dataset and statistical analysis may be made available upon reasonable request and with institutional data sharing agreements with the trial sponsor.

Data sharing details ↗ · cdn.prod.website-files.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2026 (actual). Primary completion is estimated for Jan 2030, 47 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Feb 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2024
First posted
Oct 21, 2024
StartActual
Feb 23, 2026was Jan 2026
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2030
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 15, 2026→Feb 23, 2026
Nov 12, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedPatient is taking (or will imminently start) aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease)
Exclusion criteria
  • EditedActive bleeding (allowing up to 3 days120 hours from platform entry to randomize in the event anti-thrombotic therapy is resumed)
  • EditedConcomitant receipt of an oral factor Xa inhibitor (apixaban, rivaroxaban, or edoxaban) or dabigatran
Nov 12, 2026
Interventions
Arm changed Change to clopidogrel→Change to clopidogrel 75mg per day
Nov 12, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionDesirability of Outcome Ranking (DOOR): how it is measured was reworded
Nov 12, 2026
Secondary outcomes
1 time frame changed, 1 added, 1 description edited
What changed in the outcomes
  • AddedLength of stayTime frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
  • Time frameAll cause mortalityDay 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119) → At Days 14, 28, 42 and 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
  • DescriptionInfectious Complications: how it is measured was reworded
Nov 12, 2026
Show all 2 updates
  1. Nov 17, 2026
    Minor edits only
    + 1 other change: data sharing statement
  2. Nov 12, 2026
    Start date Jan 15, 2026→Feb 23, 2026
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatient is taking (or will imminently start) aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease)
    Exclusion criteria
    • EditedActive bleeding (allowing up to 3 days120 hours from platform entry to randomize in the event anti-thrombotic therapy is resumed)
    • EditedConcomitant receipt of an oral factor Xa inhibitor (apixaban, rivaroxaban, or edoxaban) or dabigatran
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionDesirability of Outcome Ranking (DOOR): how it is measured was reworded
    Secondary outcomes 1 time frame changed, 1 added, 1 description edited
    What changed in the outcomes
    • AddedLength of stayTime frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
    • Time frameAll cause mortalityDay 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119) → At Days 14, 28, 42 and 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
    • DescriptionInfectious Complications: how it is measured was reworded
    Interventions Arm changed Change to clopidogrel→Change to clopidogrel 75mg per day
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06650488
Lead sponsor
Todd C. Lee MD MPH FIDSA
Responsible party
Todd C. Lee MD MPH FIDSA (Associate Professor of Medicine and Staff Scientist, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Sponsor-investigator
First posted
Oct 21, 2024
Start date
Feb 23, 2026
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Nov 20, 2026

Study contacts

Fatima Amari
Contact
fatima.amari@rimuhc.ca
5149341934 ext. 23730
Todd C Lee, MD MPH FIDSA
principal investigator · Research Institute of the McGill University Health Centre
Emily G McDonald, MD MSc
principal investigator · Research Institute of the McGill University Health Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion